IDBS announced that BASF has selected IDBS to deliver a data management and process development platform across its global research organization.
Sistemic Ltd and Roslin Cells Ltd signed a Memorandum of Understanding to promote the development of new technologies for the standardisation of the manufacture of stem cells for their use in cell therapy and drug development screening.
GenoLogics announced its updated LIMS, designed to provide the features necessary for mainstream adoption of the most advanced sequencing technologies while supporting existing genotyping platforms.
Honeywell announced the introduction of an RNA reagent for use in developing advanced therapeutic medicines. The Burdick & Jackson rBMI activator, is designed to help laboratories reduce the use of costly amidites.
Talon Therapeutics, Inc. announced the initiation of a Phase 3 Study of Marqibo in elderly patients with newly diagnosed aggressive Non-Hodgkin's Lymphoma to be conducted by the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Nymox Pharmaceutical Corporation announced that recruitment will begin for NX02-0020, a small open-label short-term safety study of NX-1207, the company's Phase 3 drug for benign prostatic hyperplasia.
Odyssey Thera, Inc. announced that the United States Patent and Trademark Office granted U.S. Patent No. 7,935,493, entitled "Protein fragment complementation assays for high-throughput and high-content screening."
Affymetrix, Inc. announced that the U.S. Food and Drug Administration has cleared the addition of new gene expression reagents as accessories to its GeneChip Microarray Instrument System for in vitro diagnostic (IVD) use.
Abbott Laboratories said its drug Humira met key treatment goals in a late-stage study focusing on ulcerative colitis. Ulcerative colitis is a chronic inflammatory bowel disease affecting nearly 700,000 people in the U.S.
Bayer HealthCare Pharmaceuticals Inc. said that the Food and Drug Administration will conduct a fast track review of its cancer drug candidate regorafenib.
Avanir Pharmaceuticals Inc. reported a bigger loss for its fiscal second quarter due to costs to launch the drug Nuedexta. Nuedexta is the first and only FDA-approved treatment for pseudobulbar affect.
Johnson & Johnson said that its drug Remicade met key goals in treating pediatric patients with moderate to severe ulcerative colitis in a late-stage study.
Immunologix, Inc., Charleston, S.C., and DavosPharma, Upper Saddle River, N.J. have formed a strategic alliance whereby DavosPharma, a provider of discovery, chemistry, and formulation services, will represent and market 100% human antibodies produced by Immunologix.
The company is currently enrolling a Phase 3 clinical trial referred to as SYNERGY, to be conducted in approximately 123 cancer centers to evaluate a survival benefit for custirsen in combination with first-line docetaxel treatment in approximately 800 patients with castration-resistant prostate cancer (CRPC).